|Day's Range||47.33 - 47.88|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.54|
|Dividend & Yield||1.64 (3.41%)|
|1y Target Est||53.25|
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
GUILDFORD, England , July 21, 2017 /PRNewswire/ -- FOR UK MEDIA ONLY First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis Sanofi and its ...